SARS-CoV-2, Flu A, Flu B & RSV Antibody Pairs For combo rapid antigen tests
A key focus for managing the COVID-19 pandemic during the flu season is diagnostic testing that can differentiate SARS-CoV-2 from other respiratory infections that have similar symptoms. Several immunoassays and molecular multiplex tests for SARS-CoV-2, Flu A, Flu B and RSV have been EUA approved by the FDA or received a CE mark. Rapid point-of-care lateral flow assays pose a significant benefit for clinicians as it allows them to differentially diagnose a patient with respiratory symptoms using a single swab, all within one appointment. A successful multiplex assay must demonstrate high specificity for each disease with no cross-reactivity. In addition, the sensitivity of the assay needs to meet the same limit of detection as a singleplex assay in order to be effective. This requires using monoclonal antibodies that have high affinity and specificity for their target molecule.
High Sensitivity MAb Pairs
Meridian Life Science has several high performing pairs for SARS-CoV-2, RSV, Flu A and Flu B which are ideal for use in a multiplex point-of-care assay.
*Pair detects Omicron down to 1.31 x 10 2 PFU/mL, and 1.88 x 10 2 PFU/mL for other variants.
Ordering information: USA 5171 Wilfong Road
Email: firstname.lastname@example.org Orders: email@example.com www.MeridianLifeScience.com
Memphis, Tennessee 38134 Phone: +1 901-382-8716 Fax: +1 901-333-8223
Connect with us:
ISO 13485 Certified
Powered by FlippingBook